2021
DOI: 10.1016/j.apsb.2020.11.004
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of 4-arylthiophene-3-carboxylic acid as inhibitor of ANO1 and its effect as analgesic agent

Abstract: Anoctamin 1 (ANO1) is a kind of calcium-activated chloride channel involved in nerve depolarization. ANO1 inhibitors display significant analgesic activity by the local peripheral and intrathecal administration. In this study, several thiophenecarboxylic acid and benzoic acid derivatives were identified as novel ANO1 inhibitors through the shape-based virtual screening, among which the 4-arylthiophene-3-carboxylic acid analogues with the best ANO1 inhibitory activity were designed, synthesized and compound … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 45 publications
0
7
0
Order By: Relevance
“…High-throughput drug screening and computer-aided drug design have identified an array of TMEM16A activators and potentiators, among which ETX001, a potentiator of TMEM16A, has entered clinical trials as therapeutic agent for cystic fibrosis ( 7 ). Meanwhile, a large number of TMEM16A inhibitors have been identified, including natural products Cepharanthine ( 8 ), Evodiamine ( 9 ), Honokiol ( 10 ), and Luteolin ( 11 ) and synthetic compounds Ani9 ( 12 ), CaCC inh -A01 ( 13 ), T16A inh -A01 ( 14 ), Monna ( 15 ), and 4-arylthiophene-3-carboxylic acid ( 16 ). These inhibitors have shown potential therapeutic effects in the laboratory against TMEM16A-related diseases such as hypertension, cancer, and secretory diarrhea ( 7 ).…”
mentioning
confidence: 99%
“…High-throughput drug screening and computer-aided drug design have identified an array of TMEM16A activators and potentiators, among which ETX001, a potentiator of TMEM16A, has entered clinical trials as therapeutic agent for cystic fibrosis ( 7 ). Meanwhile, a large number of TMEM16A inhibitors have been identified, including natural products Cepharanthine ( 8 ), Evodiamine ( 9 ), Honokiol ( 10 ), and Luteolin ( 11 ) and synthetic compounds Ani9 ( 12 ), CaCC inh -A01 ( 13 ), T16A inh -A01 ( 14 ), Monna ( 15 ), and 4-arylthiophene-3-carboxylic acid ( 16 ). These inhibitors have shown potential therapeutic effects in the laboratory against TMEM16A-related diseases such as hypertension, cancer, and secretory diarrhea ( 7 ).…”
mentioning
confidence: 99%
“…S12). More interestingly, we detected a specific expression of pain receptors Ano1 ( 48 ) and Trpc1 ( 49 ) in the MNTs ( Fig. 4H ) and connection of synaptophysin-expressing MNTs in the LLC tumor in vivo and neurocircuit formation of BMDM-derived MNTs in vitro (fig.…”
Section: Resultsmentioning
confidence: 80%
“…The four systems were performed with two rounds of energy minimization as reported previously by a combination of steepest descent and conjugate gradient minimizations ( Lu et al, 2019b ; Mahalapbutr et al, 2020 ; Shi et al, 2020 ; Vatansever et al, 2020 ; Wang et al, 2021a ; Lu et al, 2021b ). Afterwards, 500 ps heating, and 1,000 ps equilibration at 300 K under the NVT ensemble were performed with all heavy atoms of protein-ligand complexes fixed by a 10 kcal/(mol Å 2 ) force constant.…”
Section: Methodsmentioning
confidence: 99%